Menu Search
Equities

Recursion Pharmaceuticals Inc

RXRX:BRN

Recursion Pharmaceuticals Inc

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

  • Revenue in USD (TTM)65.18m
  • Net income in USD-377.75m
  • Incorporated2013
  • Employees500.00
  • Location
    Recursion Pharmaceuticals Inc41S Rio Grande StreetSALT LAKE CITY 84101United StatesUSA
  • Phone+1 (385) 269-0203
  • Fax+1 (801) 581-7895
  • Websitehttps://www.recursion.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RXRX:NSQ since
announced		Transaction
value
Exscientia PLCAnnounced08 Aug 202408 Aug 2024Announced-10.52%427.00m
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.